- Home
- HURA vs SGMT Comparison
HURA vs SGMT Comparison
Compare HURA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HURA | SGMT |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 169.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | HURA | SGMT |
|---|---|---|
| Price | $2.07 | $7.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.50 | ★ $26.13 |
| AVG Volume (30 Days) | 327.9K | ★ 923.6K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $4.50 |
| 52 Week High | $3.90 | $10.06 |
Technical Indicators
Market Signals| Indicator | HURA | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 47.38 |
| Support Level | $1.82 | $7.04 |
| Resistance Level | $2.20 | $7.39 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 1.32 | 21.37 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.